Diabetes and the Lung—Cause and Consequence
Saturday, June 22, at 4:30 p.m. ET
Room W414
Orange County Convention Center
(Livestream Available)
GLP-1 Receptor Agonists and the Respiratory Outcomes in Patients with Asthma and Chronic Obstructive Pulmonary Disease
Dinah Foer, MD
Assistant Professor,
Brigham and Women’s Hospital
What is your presentation about?
Drawing from the diabetes, pulmonary, and allergy literature, this talk will highlight preclinical and clinical studies suggestive of a glucagon-like peptide-1 (GLP-1) receptor agonist benefit on airway inflammation in asthma and COPD. The talk will review limitations of studies to date, active areas of research, and implications for clinical care.
How do you hope your presentation will impact diabetes research or care?
Current type 2 diabetes paradigms embrace diabetes medication choice in the context of diabetes comorbidities (CVD, CHF, obesity)—comorbid respiratory diseases are not among them. Yet, the published preclinical and clinical literature support that there are uniquely higher asthma and COPD risks for patients with diabetes, and there is suggestive data for diabetes treatment-specific benefits on airway inflammation. My hope is to draw attention to this intersection of diabetes and the lung to promote research and ultimately inform care for this population.
How did you become involved with this area of diabetes research or care?
Throughout medical school I was fortunate to work in an endocrinology lab and train with a wonderful mentor (Karl Insogna, MD) whose devotion to his patients and science sparked my love for research. Although I ended up specializing in allergy/clinical immunology, I always kept my endocrinology training close to heart. In studying asthma and diabetes, I’ve been able to pursue an interdisciplinary path that unites my research and clinical training.